MDCX Director Reports 25,000 Stock Options at $3.08 鈥� Form 3 Filing

Q: Who is the reporting person in Medicus Pharma (MDCX) Form 3?

The reporting person is Cathy McMorris Rodgers , listed as a director of Medicus Pharma.

Q: How many stock options does Cathy McMorris Rodgers report owning in MDCX?

She reports 25,000 stock options for Medicus Pharma common shares.

Q: What is the exercise price and expiration date of the reported options?

The options are exercisable at $3.08 and expire on 22-Jul-2030 .

Q: Is this Form 3 filed by a single reporting person or a group?

The form is filed by one reporting person only.

[Form 3] Medicus Pharma Ltd. Initial Statement of Beneficial Ownership

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Medicus Pharma Ltd. (MDCX) Form 3: Newly designated director Cathy McMorris Rodgers has filed her initial beneficial ownership report. Her sole holding is a stock option for 25,000 common shares granted on 22-Jul-2025 with a $3.08 exercise price. The option vests quarterly in four equal tranches over one year and expires on 22-Jul-2030. No common shares or additional derivatives are listed. The filing is made by a single reporting person and includes a power-of-attorney executed by Raza Bokhari on her behalf.

Insights

TL;DR: Routine Form 3; director discloses 25k options at $3.08鈥攎inimal immediate valuation impact.

This filing merely establishes insider reporting compliance for a new board member. The option grant is typical director compensation, representing potential dilution of 25,000 shares, which is likely immaterial relative to Medicus Pharma鈥檚 outstanding share count (not provided here). No open-market purchases or sales were reported, so there is no direct signal on sentiment or near-term cash outlay. Overall, the disclosure is neutral for investors.

TL;DR: Filing improves governance transparency; aligns new director incentives via time-based vesting.

The quarterly vesting schedule over one year ties the director鈥檚 upside to short-term execution, while the five-year term (2025-2030) maintains longer-term alignment. Inclusion of a power-of-attorney ensures timely future Section 16 reporting. Although standard, such disclosures support best practices and may marginally enhance investor confidence.

07/31/2025 - 10:36 AM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rodgers Cathy McMorris

(Last)

(First)

(Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN

19428

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/22/2025

3. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	07/22/2030	Common Shares	25,000	$3.08	D

Explanation of Responses:

1. The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year.

Remarks:

Exhibit List - Exhibit 24.1 - Power of Attorney

	/s/ Raza Bokhari, as Attorney-in-Fact, for Cathy McMorris Rodgers	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

Who is the reporting person in Medicus Pharma (MDCX) Form 3?

The reporting person is Cathy McMorris Rodgers, listed as a director of Medicus Pharma.

How many stock options does Cathy McMorris Rodgers report owning in MDCX?

She reports 25,000 stock options for Medicus Pharma common shares.

What is the exercise price and expiration date of the reported options?

The options are exercisable at $3.08 and expire on 22-Jul-2030.

When do the director鈥檚 options vest?

They vest quarterly in four equal installments over the year following the 22-Jul-2025 grant date.

Is this Form 3 filed by a single reporting person or a group?

The form is filed by one reporting person only.

What is the purpose of SEC Form 3?

Form 3 is the initial statement of beneficial ownership required of insiders (e.g., directors) under Section 16(a) of the Exchange Act.

AG真人官方

[Form 3] Medicus Pharma Ltd. Initial Statement of Beneficial Ownership

Insights

FAQ

Who is the reporting person in Medicus Pharma (MDCX) Form 3?

How many stock options does Cathy McMorris Rodgers report owning in MDCX?

What is the exercise price and expiration date of the reported options?

When do the director鈥檚 options vest?

Is this Form 3 filed by a single reporting person or a group?

What is the purpose of SEC Form 3?

NASDAQ:MDCX

MDCX Rankings

MDCX Latest News

MDCX Latest SEC Filings

MDCX Stock Data

AG真人官方

Trending News

[Form 3] Medicus Pharma Ltd. Initial Statement of Beneficial Ownership

Insights

Securities Analyst neutral

Corporate Governance Specialist positive

FAQ

Who is the reporting person in Medicus Pharma (MDCX) Form 3?

How many stock options does Cathy McMorris Rodgers report owning in MDCX?

What is the exercise price and expiration date of the reported options?

When do the director鈥檚 options vest?

Is this Form 3 filed by a single reporting person or a group?

What is the purpose of SEC Form 3?

NASDAQ:MDCX

MDCX Rankings

MDCX Latest News

MDCX Latest SEC Filings

MDCX Stock Data